Temporal relationship between bone loss and increased bone turnover in ovariectomized rats

1988 ◽  
Vol 43 (3) ◽  
pp. 179-183 ◽  
Author(s):  
T. J. Wronski ◽  
M. Cintrón ◽  
L. M. Dann
Keyword(s):  
Bone Loss ◽  
Bone Turnover ◽  
Temporal Relationship ◽  
Ovariectomized Rats

Temporal relationship between bone loss and increased bone turnover: A longitudinal study following natural menopause

1995 ◽  
Vol 18 (9) ◽  
pp. 723-728 ◽  
Author(s):  
R. Rosso ◽  
S. Minisola ◽  
A. Scarda ◽  
M. T. Pacitti ◽  
V. Carnevale ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Bone Loss ◽  
Bone Turnover ◽  
Temporal Relationship ◽  
Natural Menopause

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats

Bone ◽  
1995 ◽  
Vol 17 (5) ◽  
pp. 491-496 ◽  
Author(s):  
H.Z. Ke ◽  
H.K. Chen ◽  
H. Qi ◽  
C.M. Pirie ◽  
H.A. Simmons ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Turnover ◽  
Cancellous Bone ◽  
Axial Skeleton ◽  
Ovariectomized Rats

CP-336,156, a new estrogen agonist/antagonist, inhibits bone turnover and prevents bone loss in ovariectomized rats

Bone ◽  
1996 ◽  
Vol 19 (3) ◽  
pp. 145
Author(s):  
H.Z. Ke ◽  
H. Qi ◽  
D.T. Crawford ◽  
K.L. Chidsey-Frink ◽  
H.A. Simmons ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Turnover ◽  
Ovariectomized Rats

Impaired Estrogen Sensitivity in Bone by Inhibiting Both Estrogen Receptor a and b Pathways*

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Bone Loss ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Female Rats ◽  
Wild Type ◽  
Mineral Density ◽  
Transgenic Rats ◽  
Estrogen Sensitivity

Although it is well established that estrogen deficiencycauses osteoporosis among the postmenopausalwomen, the involvement of estrogen receptor (ER) in itspathogenesis still remains uncertain. In the presentstudy, we have generated rats harboring a dominantnegative ERa, which inhibits the actions of not only ERabut also recently identified ERb. Contrary to our expectation,the bone mineral density (BMD) of the resultingtransgenic female rats was maintained at the same levelwith that of the wild-type littermates when sham-operated.In addition, ovariectomy-induced bone loss wasobserved almost equally in both groups. Strikingly, however,the BMD of the transgenic female rats, after ovariectomized,remained decreased even if 17b-estradiol(E2) was administrated, whereas, in contrast, the decreaseof littermate BMD was completely prevented byE2. Moreover, bone histomorphometrical analysis ofovariectomized transgenic rats revealed that the higherrates of bone turnover still remained after treatmentwith E2. These results demonstrate that the preventionfrom the ovariectomy-induced bone loss by estrogen ismediated by ER pathways and that the maintenanceof BMD before ovariectomy might be compensatedby other mechanisms distinct from ERa and ERbpathways.

scholarly journals Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats

2011 ◽  
Vol 212 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Rana Samadfam ◽  
Malaika Awori ◽  
Agnes Bénardeau ◽  
Frieder Bauss ◽  
Elena Sebokova ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Trabecular Bone ◽  
Bone Mineral ◽  
Combination Treatment ◽  
Mass Gain ◽  
Ovariectomized Rats ◽  
Concomitant Treatment ◽  
Mineral Density ◽  
Ovx Rats

Peroxisome proliferator-activated receptor (PPAR) γ agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Data regarding bone effects of PPARα agonists (including fenofibrate (Feno)) are limited, although animal studies suggest that Feno may increase bone mass. This study investigated the effects of a 13-week oral combination treatment with Pio (10 mg/kg per day)+Feno (25 mg/kg per day) on body composition and bone mass parameters compared with Pio or Feno alone in adult ovariectomized (OVX) rats, with a 4-week bone depletion period, followed by a 6-week treatment-free period. Treatment of OVX rats with Pio+Feno resulted in ∼50% lower fat mass gain compared with Pio treatment alone. Combination treatment with Pio+Feno partially prevented Pio-induced loss of bone mineral content (∼45%) and bone mineral density (BMD; ∼60%) at the lumbar spine. Similar effects of treatments were observed at the femur, most notably at sites rich in trabecular bone. At the proximal tibial metaphysis, concomitant treatment with Pio+Feno prevented Pio exacerbation of ovariectomy-induced loss of trabecular bone, resulting in BMD values in the Pio+Feno group comparable to OVX controls. Discontinuation of Pio or Feno treatment of OVX rats was associated with partial reversal of effects on bone loss or bone mass gain, respectively, while values in the Pio+Feno group remained comparable to OVX controls. These data suggest that concurrent/dual agonism of PPARγ and PPARα may reduce the negative effects of PPARγ agonism on bone mass.

Sign in / Sign up

Export Citation Format

Share Document